Northland initiated coverage of Connect Biopharma (CNTB) with an Outperform rating and $7.50 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma Ends ADS Agreement with Deutsche Bank
- Connect Biopharma plans to terminate ADR program, list shares on Nasdaq
- Connect Biopharma Regains Nasdaq Compliance
- Connect Biopharma regains Nasdaq compliance
- Connect Biopharma Holdings: A Promising Investment with Strategic Drug Developments and Strong Financial Position